Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update

Janux Therapeutics, Inc. (NASDAQ:JANX) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 9,239,650 shares, a growth of 24.9% from the December 15th total of 7,395,136 shares. Based on an average daily volume of 2,641,124 shares, the short-interest ratio is presently 3.5 days. Currently, 21.8% of the company’s stock are sold short. Currently, 21.8% of the company’s stock are sold short. Based on an average daily volume of 2,641,124 shares, the short-interest ratio is presently 3.5 days.

Insider Activity

In related news, insider Zachariah Mciver sold 2,714 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $37,263.22. Following the transaction, the insider directly owned 23,286 shares of the company’s stock, valued at approximately $319,716.78. This represents a 10.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas Diraimondo sold 2,505 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $34,393.65. Following the completion of the transaction, the insider owned 124,425 shares in the company, valued at approximately $1,708,355.25. The trade was a 1.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 42,364 shares of company stock valued at $972,185. Corporate insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds have recently made changes to their positions in JANX. FNY Investment Advisers LLC grew its stake in shares of Janux Therapeutics by 97.7% during the 4th quarter. FNY Investment Advisers LLC now owns 10,300 shares of the company’s stock worth $142,000 after acquiring an additional 5,090 shares during the period. Congress Asset Management Co. lifted its holdings in Janux Therapeutics by 2.8% during the fourth quarter. Congress Asset Management Co. now owns 57,342 shares of the company’s stock valued at $791,000 after purchasing an additional 1,569 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Janux Therapeutics by 175.1% during the fourth quarter. SG Americas Securities LLC now owns 79,817 shares of the company’s stock valued at $1,101,000 after purchasing an additional 50,802 shares during the last quarter. Hudson Bay Capital Management LP boosted its position in Janux Therapeutics by 66.7% during the third quarter. Hudson Bay Capital Management LP now owns 50,000 shares of the company’s stock worth $1,222,000 after purchasing an additional 20,000 shares during the period. Finally, Alyeska Investment Group L.P. boosted its position in Janux Therapeutics by 64.2% during the third quarter. Alyeska Investment Group L.P. now owns 424,845 shares of the company’s stock worth $10,383,000 after purchasing an additional 166,167 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded up $0.04 during mid-day trading on Monday, hitting $13.76. 1,756,885 shares of the stock were exchanged, compared to its average volume of 1,448,795. Janux Therapeutics has a 12 month low of $13.26 and a 12 month high of $47.58. The company has a 50-day simple moving average of $19.42 and a 200 day simple moving average of $23.02. The company has a market capitalization of $827.66 million, a P/E ratio of -8.19 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. Analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Analysts Set New Price Targets

JANX has been the topic of a number of recent research reports. Stifel Nicolaus cut their target price on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. UBS Group reaffirmed a “buy” rating and issued a $57.00 price objective on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. HC Wainwright decreased their target price on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Cantor Fitzgerald dropped their price target on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 2nd. Finally, Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.08.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.